Tag Archives: guidance
September 2014 Br J Cardiol 2014;21:104
Towards personalised medicine: HEART UK 28th Annual Conference
BJCardio Staff and others
FH: improving detection in primary care The launch of the NICE (National Institute of Health and Care Excellence) guidelines for familial hypercholesterolaemia (FH) heralded great optimism for improving detection rates in primary care.1 Even with new research showing that FH is more common than previously thought,2 still around 80% of patients are not recognised. Novel detection approaches are clearly needed. Professor Nadeem Qureshi (University of Nottingham) presented preliminary findings from six GP centres taking part in FAMCHOL (Feasibility of Improving Identification of Familial Hypercholesterolaemia in General Practice: Intervention
March 2014 Br J Cardiol 2014;21:9
NICE guidance updates on statins and secondary prevention
BJCardio Staff
March 2013 Br J Cardiol 2013;20:11–13 doi:10.5837/bjc.2013.005
Underuse of beta blockers in patients with heart failure
Laxman Dubey, Paul Kalra, Henry Purcell
Our letter from Nepal below shows underuse of beta blockers is a widespread problem As outlined in the recent European Society of Cardiology (ESC) guidelines for the treatment of heart failure,1 the pivotal trials with beta blockers were conducted in patients with continuing symptoms and a persistently low ejection fraction (EF), despite treatment with an ACE inhibitor and, in most cases, a diuretic. Despite this, "there is consensus that these treatments are complementary and that a beta blocker and an ACE inhibitor should both be started as soon as possible after diagnosis of heart failure with reduced ejection fraction (HF-REF)".1
August 2012 Br J Cardiol 2012;19:107–10
NICE – final guidance on rivaroxaban in DVT
Estimates suggest there will be more than 46,000 cases of acute DVT in England and Wales during 2012, which will rise to nearly 50,000 cases by 2016, due in part to the ageing population. Professor Carole Longson, NICE Health Technology Evaluation Centre Director, said: "For many people, using warfarin is difficult because of the need for regular monitoring with blood tests, dosing adjustments, and the need to be careful about their diet because of warfarin's interaction with certain foods. Because rivaroxaban does not require frequent blood tests to monitor treatment it represents a potential benefit for many people who have had a DVT, p
Latest NICE guidance on chronic heart failure
BJ Cardio Staff
The new guideline, which covers the management of heart failure in adults in primary and secondary care, contains new and updated recommendations on diagnosis, pharmacological treatment, monitoring and rehabilitation. Key priorities for implementation in the guidance include: Referring patients with suspected heart failure and previous myocardial infarction (MI) to transthoracic Doppler 2D echocardiography and specialist assessment within two weeks. Measuring serum natriuretic peptides in patients with suspected heart failure without previous MI; referring those with very high levels of serum natriuretic peptides to urgent transthoracic Dopp
May 2002 Br J Cardiol 2002;9:303-4
NICE announce audit of secondary prevention guidance
Tom Quinn